Abstract
To the Editor: Randomized controlled clinical trials of drug-eluting stents (DES) versus bare metal stents demonstrate no differences in the cumulative 4-year incidences of death or myocardial infarction using the Academic Research Consortium definitions.1 Nevertheless, a numeric increase in the incidence of late stent thrombosis (LST) after DES implantation has been observed.2 LST attributable to DES may be explained by (1) a relationship to the antirestenotic properties of DES (reduced late lumen loss), (2) the impact of drug and polymer components on thrombosis, (3) the propensity to treat patients previously …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
